| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 0 | - | - | - |
| Research and development | 3,370 | 5,980 | 5,072 | 3,585 |
| General and administrative | 6,433 | 4,208 | 3,538 | 2,206 |
| Total operating expenses | 9,803 | 10,188 | 8,610 | 5,791 |
| Loss from operations | -9,803 | -10,188 | -8,610 | -5,791 |
| Foreign currency transaction gain (loss) | -89 | 11 | -294 | 93 |
| Gain on extinguishment of liabilities | - | - | 764 | - |
| Interest income, net | 1,011 | 823 | 823 | 604 |
| Other income (expense), net | -84 | - | -40 | 35 |
| Total other income, net | 838 | 834 | 1,253 | 732 |
| Net loss | -8,965 | -9,354 | -7,357 | -5,059 |
| Unrealized foreign currency translation gain (loss) | 89 | - | - | - |
| Total other comprehensive income (loss) | 89 | - | - | - |
| Total comprehensive loss | -8,876 | - | - | - |
| Earnings per share, basic | -0.22 | -0.24 | -0.33 | -0.48 |
| Earnings per share, diluted | -0.22 | -0.24 | -0.33 | -0.48 |
| Weighted average number of shares outstanding, basic | 41,521,280 | 38,599,453 | 22,075,332 | 10,644,533 |
| Weighted average number of shares outstanding, diluted | 41,521,280 | 38,599,453 | 22,075,332 | 10,644,533 |
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC)